someone's accumulating thru TD last whileKnow something?
Biomark receives approval for $400,000 CHRP funding
2019-04-17 09:35 ET - News Release
Mr. Rashid Ahmed reports
BIOMARK AND ITS TEAM OF COLLABORATORS SECURE CHRP FUNDING
Biomark Diagnostics Inc.'s application entitled, "Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma," submitted to the Collaborative Health Research Projects (CHRP) funding opportunity, has been approved. The application was approved by Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) and in collaboration with the Social Sciences and Humanities Research Council (SSHRC). The funding is for approximately $400,000. Biomark is the industrial partner on the grant.
The company would like to thank Dr. D. Miller, Dr. T. Klonish, Dr. T. Lakowski, Dr. M. Pitz and Dr. D. Wishart, who contributed immensely during the application process. Rashid Ahmed, president and chief executive officer, commented: "It was highly competitive, and we are delighted to be amongst a select group of applicants that secured the funding. This demonstrates the quality of our application, based on key measures, such as scientific merit, calibre of the team and potential clinical impact. Assembling a high-impact, multidisciplinary team to collaborate in developing potentially disruptive diagnostic test that can improve identification and care for patients with glioblastoma is exciting."
Biomark would like to acknowledge CIHR, NSERC and SSHRC for the funding. In addition, the company thanks the numerous reviewers for their excellent feedback.
About Biomark Diagnostics Inc.
Biomark Diagnostics is developing proprietary, non-invasive and accurate cancer diagnostic solutions that can help detect, monitor and assess treatment for cancer early and cost-effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.
We seek Safe Harbor.